TerraBioGen Signs Master License Agreement

NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

TerraBioGen Technologies Inc. (TSX VENTURE:TBG), a developer and marketer of
proprietary technologies for the production of organic-based, high-value
agricultural products from organic wastes, announces that it has signed a Master
License Agreement ("MLA") for the Middle East.


Under the terms of the Master License Agreement (MLA), the licensee is required
to pay a license fee of $1,250,000 by November 21, 2011 and an additional
$1,250,000 upon completion of a 100 tonne per day ("TPD") plant, expected to
occur in 2013. The Company will also receive royalties from the operation of
this plant and any additional plants built over a 40 year period along with
sub-licensing fees.


Blair Heffelfinger, President and CEO of TerraBioGen, said, "This is the first
MLA we have negotiated under our new regional license basis. In addition to the
license, our new MLA partner will establish a regional office to facilitate
technology transfer, product marketing, sales and customer support. This will
ensure efficient market introduction of a quality product and expand our
business opportunities. In addition, with the process review announced earlier
this year showing that a smaller scale plant such as 100 TPD can be built at a
much lower cost and generate an attractive internal return, we believe this will
facilitate technology adoption."


About TerraBioGen

Located in North Vancouver, BC, TerraBioGen Technologies Inc. is committed to
research and development to continue to improve the efficiency of its technology
and the quality of its agricultural products. It is further committed to
developing a world-wide marketing capability to ensure market acceptance of its
products.


This news release contains certain statements that may be deemed
"forward-looking" statements. Forward looking statements are statements that are
not historical facts and are generally, but not always, identified by the words
"expects", "plans", "anticipates", "believes", "intends", "estimates",
"projects", "potential" and similar expressions, or that events or conditions
"will", "would", "may", "could" or "should" occur. Although TerraBioGen believes
the expectations expressed in such forward-looking statements are based on
reasonable assumptions, such statements are not guarantees of future performance
and actual results may differ materially from those in forward looking
statements. Forward looking statements are based on the beliefs, estimates and
opinions of TerraBioGen's management on the date the statements are made. Except
as required by law, TerraBioGen undertakes no obligation to update these
forward-looking statements in the event that management's beliefs, estimates or
opinions, or other factors, should change.


THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR
DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES,
AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN. THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF
1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD
IN THE UNITED STATES OR TO U.S. PERSONS UNLESS REGISTERED OR EXEMPT THEREFROM.

Terrabiogen Technologies (TSXV:TBG)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024